section name header

Pronunciation

en-FOO-veer-tide

Classifications

Therapeutic Classification: antiretrovirals

Pharmacologic Classification: fusion inhibitors

Indications

REMS


Action

  • Prevents entry of HIV-1 into cells by interfering with the fusion of the virus with cellular membranes.
Therapeutic effects:
  • Decreased replication of the HIV virus.
  • Slowed progression of HIV infection with decreased occurrence of sequelae.
  • Improved CD4 cell count.

Pharmacokinetics

Absorption: 84% absorbed following SUBQ administration.

Distribution: 5.5 L.

Protein Binding: 92% bound to plasma proteins.

Metabolism/Excretion: Broken down into component amino acids and then recycled in body pool.

Half-Life: 3.8 hr.

Time/Action Profile

(blood levels)

ROUTEONSETPEAKDURATION
SUBQUnknown8 hr12 hr





Contraind./Precautions

Contraindicated in:

Use Cautiously in:

Adv. Reactions/Side Effects

EENT: conjunctivitis

GI: diarrhea, nausea, abdominal pain, anorexia, dry mouth, PANCREATITIS, weight loss

Local: injection site reactions

MS: limb pain, myalgia

Neuro: fatigue

Resp: cough, pneumonia, sinusitis

Misc: herpes simplex, hypersensitivity reactions, immune reconstitution syndrome

Interactions

Drug-drug:

Route/Dosage

Availability

Assessment

Lab Test Considerations:

Implementation

Patient/Family Teaching

Evaluation/Desired Outcomes

US Brand Names

Fuzeon